lorvotuzumab mertansine (IMGN901) / ImmunoGen, AbbVie  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lorvotuzumab mertansine (IMGN901) / AbbVie
NCT00065429: Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer

Completed
2
64
US
BB-10901
ImmunoGen, Inc.
Small Cell Lung Cancer
11/08
12/08
NCT02420873: An Open-label Phase II Study of Lorvotuzumab Mertansine

Completed
2
9
US
Lorvotuzumab Mertansine (IMGN901)
M.D. Anderson Cancer Center, ImmunoGen, Inc.
Leukemia
06/17
06/17
NCT02452554: Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Completed
2
62
US
Laboratory Biomarker Analysis, Lorvotuzumab Mertansine, Anti-Human NCAM-1 Monoclonal Antibody N901, BB-10901, huN901-DM1, IMGN901, Pharmacological Study
Children's Oncology Group, National Cancer Institute (NCI)
Pleuropulmonary Blastoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Recurrent Synovial Sarcoma, Wilms Tumor
06/17
09/21
NCT01237678 / 2010-022950-17: A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

Terminated
1/2
181
US, Canada, Europe
IMGN901, BB-10901, Lorvotuzumab mertansine, Carboplatin and Etoposide, Toposar®, VePesid®, Etopophos®
ImmunoGen, Inc.
Small Cell Lung Cancer
05/15
05/15

Download Options